PSMA THERAPEUTICS
PSMA Therapeutics is a subsidiary of Noria to advance the platform of prostate-specific membrane antigen (PSMA) targeting radiotherapeutics.
PSMA THERAPEUTICS
Industry:
Therapeutics
Address:
New York, New York, United States
Country:
United States
Status:
Active
More informations about "PSMA Therapeutics"
Bayer acquires Noria and PSMA Therapeutics to …
Berlin, Germany, June 3, 2021 - Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.Through this acquisition Bayer will obtain exclusive rights to a …See details»
PSMA Therapeutics - Crunchbase Company Profile & Funding
Sub-Organization of . Noria Therapeutics . Operating Status Active; Company Type For Profit; PSMA Therapeutics is a subsidiary of Noria to advance the platform of prostate-specific …See details»
Breaking News: Expanded FDA Approval of 177Lutetium-PSMA-617
Mar 28, 2025 The FDA approval of 177 Lutetium-PSMA-617 (Lu-PSMA) is now expanded to patients with metastatic castration-resistant prostate cancer (mCRPC) who have received an …See details»
PSMA-Targeting Radiopharmaceuticals for Prostate Cancer …
A .gov website belongs to an official government organization in the United States . Secure .gov websites use HTTPS ... PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: …See details»
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 3, 2021 Broadens company’s oncology platform of Targeted Alpha Therapies (TATs) Acquisition includes actinium-225 labeled differentiated prostate-specific membrane antigen …See details»
Bayer Inks Pharma Acquisition Deal to Advance Cancer Therapies
Jun 8, 2021 Bayer recently entered into a pharma acquisition deal with Noria Therapeutics and PSMA Therapeutics to expand its prostate cancer therapies pipeline. As part of the …See details»
PSMA Therapeutics - Products, Competitors, Financials, Employees ...
In June 2021, Bayer AG announced the acquisition of Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer AG will obtain exclusive rights to a …See details»
PSMA-Directed Therapies and Diagnostics Expand …
May 14, 2021 PSMA-Directed Therapeutics: Burgeoning Field . Imaging with Ga 68 PSMA-11 is being considered as a tool to guide targeted treatment. “There’s a whole field of PSMA-directed therapeutics,” said Michael Morris, MD, clinical …See details»
Bayer Acquires Noria and PSMA Therapeutics to Expand Pipeline …
Jun 8, 2021 Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. Through this acquisition, Bayer will …See details»
Technology | Prostate Specific Membrane Antigen …
PSMA is expressed on greater than 90% of all prostate cancers. The expression increases as the cancer spreads and metastasizes and expression is strong in late-stage androgen-independent prostate tumors. ... Companion …See details»
FDA approves Novartis radioligand therapy Pluvicto® for earlier …
Mar 28, 2025 Pluvicto is the first and only targeted radioligand therapy for patients with PSMA-positive mCRPC before the need for chemotherapy. Novartis is investigating Pluvicto in earlier …See details»
PSMA-Targeted Therapy: Advancements in Detection and …
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... with theranostics being heralded as a promising frontier for …See details»
PSMA-based therapeutics for prostate cancer - PubMed
Currently, PSMA radioligand treatment of prostate cancer is approved in the metastatic stage of the disease. Meanwhile, a variety of trials exist about its possible role in less advanced stages. …See details»
Prostate-specific Membrane Antigen (PSMA): A Diagnostic and …
Oct 28, 2024 Since its discovery over 30 years ago (see Figure 1 for this and other milestones), PSMA has caught the attention of the scientific community as a potential therapeutic target, …See details»
Prostate-Specific Membrane Antigen–Targeted Therapies for …
Mar 1, 2024 The first PSMA-targeted agent approved by the US Food and Drug Administration is 177 Lu-PSMA-617. In the VISION trial (NCT03511664), 177 Lu-PSMA-617 treatment in …See details»
PSMA Therapeutics (PSMA Therapeutics) - 药物管线_专利_临床试 …
May 1, 2023 但此后拜耳还是陆续通过收购Algeta、Noria和PSMA Therapeutics等公司，来加强其在核药领域的研发和市场影响力。 通过这些收购，拜耳不仅获得了基于锕-225和一种靶向 …See details»
CART-PSMA cells(Nova Therapeutics LLC) - Drug Targets ... - Patsnap
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced …See details»
Next-Generation PSMA Radioligands "Presentation" - Martin Pomper
2 hours ago At the 2025 UCSF-UCLA PSMA Conference, Martin Pomper discusses innovative approaches in PSMA-targeted radiopharmaceuticals beyond established agents. He reviews …See details»
PSMA-based therapeutics for prostate cancer - Taylor & Francis …
Jul 31, 2024 A literature review is presented about the implications of PSMA radiolabels on prostate cancer treatment. PSMA tracers were initially used as an imaging technique. …See details»
Prostate-specific membrane antigen (PSMA) Therapeutics
Oct 7, 2021 Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed on prostate cancer cells making it an optimal target for imaging and therapy …See details»